• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hinge Health reports fourth quarter and full year 2025 financial results

    2/10/26 4:05:00 PM ET
    $HNGE
    EDP Services
    Technology
    Get the next $HNGE alert in real time by email

    Hinge Health, Inc. (NYSE:HNGE) today announced record financial results for the quarter and year ended December 31, 2025.

    "We closed out the year with an exceptional quarter and a strong selling season, driving our highest win rates to date and greatest number of eligible lives added in any year," said Daniel Perez, Co-Founder and CEO, Hinge Health. "Our commercial momentum, combined with expanding margins and strong cash generation, gives us confidence in our ability to continue automating care delivery, sustain our position as a leader in digital musculoskeletal care, and drive attractive growth and increased margins in 2026."

    Fourth Quarter 2025 Financial Highlights:

    • Revenue increased 46% year over year to $170.7 million compared to revenue of $117.3 million in Q4 2024.
    • GAAP gross margin was 84% compared to 82% in Q4 2024. Non-GAAP gross margin was 85% compared to 82% in Q4 2024.
    • GAAP income from operations increased 31% to $27.3 million compared to GAAP income from operations of $20.9 million in Q4 2024. Non-GAAP income from operations increased 124% to $48.0 million compared to non-GAAP income from operations of $21.4 million in Q4 2024.
    • GAAP diluted net income per share was $0.37. Non-GAAP diluted net income per share was $0.49.
    • Net cash provided by operating activities increased 67% to $63.9 million compared to net cash provided by operating activities of $38.3 million in Q4 2024. Free cash flow increased 65% to $61.5 million compared to free cash flow of $37.3 million in Q4 2024.
    • Cash, cash equivalents, marketable securities and restricted cash were $478.8 million as of December 31, 2025.

    Year Ended 2025 Financial Highlights:

    • Revenue increased 51% year over year to $587.9 million compared to revenue of $390.4 million in 2024.
    • GAAP gross margin was 80% compared to 77% in 2024. Non-GAAP gross margin was 83% compared to 78% in 2024.
    • GAAP loss from operations was $546.4 million compared to GAAP loss from operations of $31.9 million in 2024. Non-GAAP income from operations was $119.5 million compared to non-GAAP loss from operations of $26.1 million in 2024.
    • Net cash provided by operating activities increased 250% to $171.4 million compared to net cash provided by operating activities of $49.0 million in 2024. Free cash flow increased 297% to $179.6 million compared to free cash flow of $45.2 million in 2024.

    Company Highlights and Key Metrics as of December 31, 2025:

    • LTM calculated billings increased 44% year over year to $671.4 million, compared to $467.5 million as of December 31, 2024.
    • Annual yield of 3.9% in 2025, up 50 basis points compared to 3.4% in 2024.
    • Number of clients increased 25% year over year to 2,830 clients, compared to 2,256 clients as of December 31, 2024.
    • Number of contracted lives increased to 25 million, compared to 20 million as of December 31, 2024.
    • Number of members increased 47% year over year to 782,890, compared to 532,326 as of December 31, 2024.
    • LTM average eligible lives increased 28% year over year to 20.1 million, compared to 15.7 million as of December 31, 2024.
    • Rule of 40 metric was 81 in 2025 compared to 45 in 2024, measured by revenue growth plus free cash flow margin during the period.

    Financial Outlook:

    We are providing the following guidance for our first quarter 2026 and full year 2026:

    • Q1 2026: We expect revenue to be between $171 million and $173 million, reflecting year over year growth of 39% at the midpoint. We expect non-GAAP income from operations to be between $30 million and $32 million, reflecting year over year growth of 108% and non-GAAP operating margin of 18% at the midpoint.
    • Full Year 2026: We expect revenue to be between $732 million and $742 million, reflecting year over year growth of 25% at the midpoint. We expect non-GAAP income from operations to be between $151 million and $156 million, reflecting year over year growth of 29% and non-GAAP operating margin of 21% at the midpoint.

    Statement Regarding Use of Non-GAAP Financial Measures

    This press release uses non-GAAP financial measures, which are not calculated in accordance with generally accepted accounting principles of the United States (GAAP). For more information about these non-GAAP financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP, please see the "Non-GAAP Financial Measures" section below.

    Moreover, we have not reconciled our non-GAAP income (loss) from operations guidance to GAAP income (loss) from operations because we do not and are not able to provide guidance for GAAP income (loss) from operations due to the uncertainty and potential variability of stock-based compensation expense, employer payroll tax expense related to stock-based compensation, amortization of intangible assets and adjustments, such as the excess inventory and transition charges, restructuring and other expense and acquisition related expense, which are reconciling items between non-GAAP and GAAP income (loss) from operations. Because such items cannot be provided without unreasonable efforts, we are unable to provide a reconciliation of the non-GAAP financial measure guidance to the corresponding GAAP measures. However, such items could have a significant impact on our future GAAP income (loss) from operations.

    Share Repurchase Program

    In November 2025, our board of directors authorized a share repurchase program pursuant to which we may repurchase up to $250.0 million in aggregate value of our outstanding Class A common stock. During Q4 2025, we repurchased $65.0 million in aggregate value of shares of our Class A common stock.

    Hinge Health Earnings Webcast

    We will host a conference call and webcast for investors on February 10, 2026 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss our financial results, business highlights and financial outlook. The live webcast of the conference call can be accessed by registering online at ir.hingehealth.com/events-presentations. Following completion of the events, a webcast replay will also be available at ir.hingehealth.com for 12 months.

    About Hinge Health

    Hinge Health is focused on scaling and automating the delivery of health care, starting with musculoskeletal conditions. Leveraging an AI-powered care model, wearable devices and access to expert clinicians, Hinge Health delivers personalized, evidence-based care that helps people move beyond pain, improving member outcomes and experiences and reducing costs for clients. The company is headquartered in San Francisco, California.

    Available Information

    Our investors and others should note that we announce material information to the public about our company, products and services, and other matters related to our company through a variety of means, including filings with the U.S. Securities and Exchange Commission ("SEC"), the investor relations page on our website (ir.hingehealth.com), press releases, public conference calls, and webcasts in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our obligations under Regulation FD.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," or "will," or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this release include, but are not limited to, statements regarding our expectations regarding our financial position and operating performance, including our outlook and guidance for the first quarter of 2026 and guidance for full year 2026 and our assumptions underlying such guidance; our ability to drive future growth and execute on our goals and strategies; and our expectations regarding our product innovation. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including those more fully described in our filings with the SEC, including in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 7, 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2025, when filed with the SEC. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligations to update any forward-looking statements, except as required by law.

     

    HINGE HEALTH, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (unaudited)

    (in thousands, except par value data)

     

     

     

     

     

    Year Ended

    December 31,

     

     

    2025

     

    2024

    Assets

     

     

     

     

    Current assets:

     

     

     

     

    Cash and cash equivalents

     

    $

    207,995

     

     

    $

    300,785

     

    Short-term marketable securities

     

     

    155,867

     

     

     

    165,787

     

    Accounts receivable, net of allowance for credit losses of $6,092 and $6,470 as of December 31, 2025 and December 31, 2024, respectively

     

     

    66,061

     

     

     

    42,495

     

    Deferred commissions

     

     

    31,344

     

     

     

    18,615

     

    Inventory

     

     

    15,636

     

     

     

    10,873

     

    Prepaid expenses and other current assets

     

     

    57,001

     

     

     

    44,891

     

    Total current assets

     

     

    533,904

     

     

     

    583,446

     

    Long-term marketable securities

     

     

    113,172

     

     

     

    —

     

    Goodwill

     

     

    64,096

     

     

     

    61,607

     

    Intangible assets, net

     

     

    2,512

     

     

     

    1,807

     

    Property, equipment and software, net

     

     

    10,490

     

     

     

    7,380

     

    Operating lease right-of-use assets

     

     

    6,861

     

     

     

    9,607

     

    Other assets

     

     

    13,726

     

     

     

    9,412

     

    Total assets

     

    $

    744,761

     

     

    $

    673,259

     

    Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)

     

     

     

     

    Current liabilities:

     

     

     

     

    Accounts payable and accrued liabilities

     

    $

    57,331

     

     

    $

    27,853

     

    Operating lease liabilities

     

     

    4,223

     

     

     

    3,814

     

    Deferred revenue

     

     

    300,855

     

     

     

    217,632

     

    Total current liabilities

     

     

    362,409

     

     

     

    249,299

     

    Operating lease liabilities, noncurrent

     

     

    3,816

     

     

     

    7,258

     

    Total liabilities

     

     

    366,225

     

     

     

    256,557

     

     

     

     

     

     

    Redeemable convertible preferred stock:

     

     

     

     

    Redeemable convertible preferred stock; $0.00001 par value

     

     

    199,874

     

     

     

    851,272

     

    Stockholders' equity (deficit):

     

     

     

     

    Common stock, $0.00001 par value

     

     

    —

     

     

     

    —

     

    Class A common stock, $0.00001 par value

     

     

    —

     

     

     

    —

     

    Class B common stock, $0.00001 par value

     

     

    —

     

     

     

    —

     

    Additional paid-in capital

     

     

    1,229,678

     

     

     

    88,097

     

    Accumulated other comprehensive gain (loss)

     

     

    (20

    )

     

     

    68

     

    Accumulated deficit

     

     

    (1,050,996

    )

     

     

    (522,735

    )

    Total stockholders' equity (deficit)

     

     

    178,662

     

     

     

    (434,570

    )

    Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)

     

    $

    744,761

     

     

    $

    673,259

     

     

    HINGE HEALTH, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (unaudited)

    (in thousands, except per share data)

     

     

     

     

     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2025

     

    2024

     

    2025

     

    2024

    Revenue

     

    $

    170,726

     

     

    $

    117,256

     

     

    $

    587,860

     

     

    $

    390,404

     

    Cost of revenue

     

     

    26,699

     

     

     

    21,168

     

     

     

    119,638

     

     

     

    90,502

     

    Gross profit

     

     

    144,027

     

     

     

    96,088

     

     

     

    468,222

     

     

     

    299,902

     

    Operating expenses:

     

     

     

     

     

     

     

     

    Research and development

     

     

    32,755

     

     

     

    22,371

     

     

     

    368,137

     

     

     

    100,839

     

    Sales and marketing

     

     

    59,487

     

     

     

    35,451

     

     

     

    316,951

     

     

     

    167,058

     

    General and administrative

     

     

    24,529

     

     

     

    17,356

     

     

     

    329,505

     

     

     

    63,915

     

    Total operating expenses

     

     

    116,771

     

     

     

    75,178

     

     

     

    1,014,593

     

     

     

    331,812

     

    Income (loss) from operations

     

     

    27,256

     

     

     

    20,910

     

     

     

    (546,371

    )

     

     

    (31,910

    )

    Other income:

     

     

     

     

     

     

     

     

    Other income, net

     

     

    4,961

     

     

     

    5,255

     

     

     

    19,108

     

     

     

    20,654

     

    Net income (loss) before income taxes

     

     

    32,217

     

     

     

    26,165

     

     

     

    (527,263

    )

     

     

    (11,256

    )

    Provision for (benefit from) income taxes

     

     

    122

     

     

     

    (951

    )

     

     

    998

     

     

     

    677

     

    Net income (loss)

     

    $

    32,095

     

     

    $

    27,116

     

     

    $

    (528,261

    )

     

    $

    (11,933

    )

    Adjustment to reflect deemed contribution from Series D and Series E redeemable convertible preferred stock extinguishment

     

     

    —

     

     

     

    —

     

     

     

    104,174

     

     

     

    —

     

    Undistributed earnings attributable to participating securities

     

     

    (1,009

    )

     

     

    (21,354

    )

     

     

    —

     

     

     

    —

     

    Net income (loss) attributable to common stockholders, basic

     

    $

    31,086

     

     

    $

    5,762

     

     

    $

    (424,087

    )

     

    $

    (11,933

    )

    Net income (loss) attributable to common stockholders, diluted

     

    $

    31,144

     

     

    $

    6,676

     

     

    $

    (424,087

    )

     

    $

    (11,933

    )

    Net income (loss) attributable to common stockholders per share:

     

     

     

     

     

     

     

     

    Basic

     

    $

    0.39

     

     

    $

    0.42

     

     

    $

    (7.77

    )

     

    $

    (0.88

    )

    Diluted

     

    $

    0.37

     

     

    $

    0.40

     

     

    $

    (7.77

    )

     

    $

    (0.88

    )

    Weighted average shares used in computing net income (loss) per share attributable to common stockholders:

     

     

     

     

     

     

     

     

    Basic

     

     

    79,521

     

     

     

    13,693

     

     

     

    54,577

     

     

     

    13,558

     

    Diluted

     

     

    84,533

     

     

     

    16,576

     

     

     

    54,577

     

     

     

    13,558

     

     

    HINGE HEALTH, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (unaudited)

    (in thousands)

     

     

     

     

     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2025

     

    2024

     

    2025

     

    2024

    Operating activities:

     

     

     

     

     

     

     

     

    Net income (loss)

     

    $

    32,095

     

     

    $

    27,116

     

     

    $

    (528,261

    )

     

    $

    (11,933

    )

    Adjustments to reconcile net income (loss) to net cash provided by operating activities:

     

     

     

     

     

     

     

     

    Depreciation and amortization

     

     

    1,223

     

     

     

    1,366

     

     

     

    5,133

     

     

     

    5,950

     

    Stock-based compensation

     

     

    17,172

     

     

     

    14

     

     

     

    643,009

     

     

     

    739

     

    Amortization of deferred commissions

     

     

    14,231

     

     

     

    9,032

     

     

     

    46,667

     

     

     

    29,914

     

    Accretion of discounts and amortization of premiums on marketable securities, net

     

     

    (15

    )

     

     

    241

     

     

     

    361

     

     

     

    537

     

    Excess and obsolete inventory charge

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    1,812

     

    Non-cash operating lease expense

     

     

    882

     

     

     

    871

     

     

     

    3,431

     

     

     

    3,649

     

    Provision for credit losses

     

     

    (279

    )

     

     

    1,471

     

     

     

    3,061

     

     

     

    5,410

     

    Deferred income taxes

     

     

    (93

    )

     

     

    (585

    )

     

     

    53

     

     

     

    (585

    )

    Other

     

     

    1

     

     

     

    (8

    )

     

     

    1

     

     

     

    7

     

    Changes in operating assets and liabilities:

     

     

     

     

     

     

     

     

    Accounts receivable

     

     

    20,983

     

     

     

    15,888

     

     

     

    (26,627

    )

     

     

    (1,340

    )

    Deferred commissions

     

     

    (25,259

    )

     

     

    (10,812

    )

     

     

    (63,579

    )

     

     

    (38,513

    )

    Inventory

     

     

    (1,824

    )

     

     

    (3,220

    )

     

     

    (4,763

    )

     

     

    608

     

    Prepaid expenses and other current assets

     

     

    (7,773

    )

     

     

    (6,719

    )

     

     

    (15,775

    )

     

     

    (9,155

    )

    Other assets

     

     

    7,968

     

     

     

    7

     

     

     

    (181

    )

     

     

    377

     

    Accounts payable and accrued liabilities

     

     

    4,417

     

     

     

    (2,819

    )

     

     

    29,407

     

     

     

    (10,975

    )

    Operating lease liabilities

     

     

    (995

    )

     

     

    (1,061

    )

     

     

    (3,719

    )

     

     

    (4,659

    )

    Deferred revenue

     

     

    1,161

     

     

     

    7,557

     

     

     

    83,223

     

     

     

    77,159

     

    Net cash provided by operating activities

     

     

    63,895

     

     

     

    38,339

     

     

     

    171,441

     

     

     

    49,002

     

    Investing activities:

     

     

     

     

     

     

     

     

    Purchase of property and equipment

     

     

    (408

    )

     

     

    (157

    )

     

     

    (708

    )

     

     

    (1,039

    )

    Capitalized internal use software

     

     

    (1,955

    )

     

     

    (873

    )

     

     

    (5,356

    )

     

     

    (2,734

    )

    Purchases of marketable securities

     

     

    (154,108

    )

     

     

    (83,278

    )

     

     

    (472,288

    )

     

     

    (324,543

    )

    Maturities of marketable securities

     

     

    118,775

     

     

     

    81,194

     

     

     

    368,589

     

     

     

    346,628

     

    Acquisition of a business

     

     

    —

     

     

     

    —

     

     

     

    (4,000

    )

     

     

    —

     

    Net cash (used in) provided by investing activities

     

     

    (37,696

    )

     

     

    (3,114

    )

     

     

    (113,763

    )

     

     

    18,312

     

    Financing activities:

     

     

     

     

     

     

     

     

    Proceeds from exercise of common stock options

     

     

    629

     

     

     

    208

     

     

     

    1,416

     

     

     

    610

     

    Issuance of common stock in connection with the employee purchase plan

     

     

    8,113

     

     

     

    —

     

     

     

    8,113

     

     

     

    —

     

    Proceeds from issuance of common stock in initial public offering, net of issuance costs

     

     

    —

     

     

     

    —

     

     

     

    255,675

     

     

     

    —

     

    Tax withholdings on settlement of restricted stock units and performance-based restricted stock units

     

     

    (22,971

    )

     

     

    —

     

     

     

    (295,229

    )

     

     

    —

     

    Payment on Repurchase Agreement with Coatue

     

     

    —

     

     

     

    —

     

     

     

    (50,000

    )

     

     

    —

     

    Repurchase and retirement of common stock

     

     

    (65,028

    )

     

     

    —

     

     

     

    (65,028

    )

     

     

    —

     

    Proceeds from repayment of non-recourse loans to employees

     

     

    —

     

     

     

    —

     

     

     

    4,934

     

     

     

    —

     

    Payments for deferred offering costs

     

     

    (288

    )

     

     

    (2,543

    )

     

     

    (10,349

    )

     

     

    (2,812

    )

    Net cash used in financing activities

     

     

    (79,545

    )

     

     

    (2,335

    )

     

     

    (150,468

    )

     

     

    (2,202

    )

    Net increase (decrease) in cash, cash equivalents and restricted cash

     

     

    (53,346

    )

     

     

    32,890

     

     

     

    (92,790

    )

     

     

    65,112

     

    Cash, cash equivalents, and restricted cash, beginning of period

     

     

    263,142

     

     

     

    269,696

     

     

     

    302,586

     

     

     

    237,474

     

    Cash, cash equivalents, and restricted cash, end of period

     

    $

    209,796

     

     

    $

    302,586

     

     

    $

    209,796

     

     

    $

    302,586

     

    Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets:

     

     

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    207,995

     

     

    $

    300,785

     

     

    $

    207,995

     

     

    $

    300,785

     

    Restricted cash

     

     

    1,801

     

     

     

    1,801

     

     

     

    1,801

     

     

     

    1,801

     

    Total cash, cash equivalents, and restricted cash

     

    $

    209,796

     

     

    $

    302,586

     

     

    $

    209,796

     

     

    $

    302,586

     

    Glossary of Terms

    LTM Calculated Billings: We believe calculated billings on a last 12-months basis helps investors better understand our performance for a particular period given the seasonality in our model due to quarterly fluctuations based on the timing of new client launches and number of intra-year launches. We anticipate that this seasonality will continue and therefore focus on LTM calculated billings. Our revenue generally does not reflect this seasonality and these quarterly fluctuations given that we recognize revenue ratably over the term that members have access to our platform. LTM calculated billings are defined as total revenue, plus the change in deferred revenue, less the change in contract assets for a given 12-month period.

    Clients: We view this number as an important metric to assess the performance of our business as an increased number of clients drives growth, increases brand awareness, and helps provide scale to our business. Clients are defined as businesses or organizations, which we call entities, that have at least one active agreement with us at the end of a particular period. Entities that procure our platform through our partners are counted as individual clients. We do not count our partners as clients, unless they also separately have at least one active client agreement with us. When a partner has an agreement with us for their fully-insured population, that partner is deemed to be one client, despite there being multiple fully-insured employers within that entity that have access to our platform.

    Members: Growth in the number of members is an indicator of the penetration we have made within our clients' eligible lives. This metric is a key driver of our calculated billings and provides an indication of our future revenue performance. We calculate the number of members at the end of a particular period based on the total number of eligible lives who have engaged with our platform in the last 12 months and whose engagements have been billed or are contractually eligible to be billed.

    LTM Average Eligible Lives: This represents the population to whom we can market and offer our solutions to. As eligible lives can fluctuate throughout the year given changes in our clients' populations, we take the average of the clients who are live in the first quarter to those who are live at the end of the last quarter in a given 12-month period to best determine the number of lives we had access to convert into members. Our management uses LTM average eligible lives to model the business and measure the enrollment we are able to achieve within our client base.

    Annual Yield: This is calculated as the number of members at the end of a given 12-month period divided by LTM average eligible lives.

    Number of Contracted Lives: Individuals within our contracted clients who have, or will have, the ability to enroll in our programs, typically employees and their adult dependents. Contracted lives include individuals within contracted clients that have not yet launched our platform, and thus such individuals are not yet eligible to be billed. Contracted lives include eligible lives.

    Non-GAAP Financial Measures

    In addition to our results prepared in accordance with GAAP, we believe the following non-GAAP financial measures, including non-GAAP gross profit and gross margin, non-GAAP income (loss) from operations and operating margin, non-GAAP operating expenses, non-GAAP net income attributable to common stockholders, diluted, non-GAAP net income per share attributable to common stockholders, diluted (which we refer to as "non-GAAP diluted net income per share") and free cash flow and free cash flow margin included in this press release, provide users of our financial information with additional useful information in evaluating our performance and liquidity and allows them to more readily compare our results across periods without the effect of non-cash and other items as detailed below. Additionally, our management and board of directors use our non-GAAP financial measures to evaluate our performance and liquidity, identify trends and make strategic decisions.

    There are limitations to the use of the non-GAAP financial measures presented in this press release. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes. Our non-GAAP financial measures should not be considered in isolation or as alternatives to gross profit, gross margin, income (loss) from operations, net income attributable to common stockholders, net income per share attributable to common stockholder, net cash provided by (used in) operating activities or any other measure of financial performance calculated and presented in accordance with GAAP.

    Non-GAAP Gross Profit and Gross Margin

    We define non-GAAP gross profit as gross profit presented in accordance with GAAP, adjusted to exclude non-cash, non-operational and non-recurring items, including excess and obsolete inventory charges related to our AI-powered motion tracking technology transition, stock-based compensation expense, employer payroll tax expense related to stock-based compensation, amortization of intangible assets, and restructuring and other expenses. We define non-GAAP gross margin as non-GAAP gross profit divided by revenue.

    The principal limitation of non-GAAP gross profit and non-GAAP gross margin is that they exclude significant expenses that are required by GAAP to be recorded in our consolidated financial statements, including non-cash expenses, and the impact of non-recurring charges that we do not consider to be indicative of our ongoing core operations.

    Non-GAAP Income (Loss) From Operations and Operating Margin

    We define non-GAAP income (loss) from operations as income (loss) from operations presented in accordance with GAAP, adjusted to exclude non-cash, non-operational and non-recurring items, including excess and obsolete inventory charges related to our AI-powered motion tracking technology transition, stock-based compensation expense, employer payroll tax expense related to stock-based compensation, amortization of intangible assets, restructuring and other expenses and acquisition-related expenses. We define non-GAAP operating margin as non-GAAP income (loss) from operations divided by revenue.

    The principal limitation of non-GAAP income (loss) from operations and non-GAAP operating margin is that they exclude significant expenses that are required by GAAP to be recorded in our consolidated financial statements, including non-cash expenses, and the impact of non-recurring charges that we do not consider to be indicative of our ongoing core operations.

    Non-GAAP Operating Expenses

    We define non-GAAP operating expenses as operating expenses presented in accordance with GAAP, adjusted to exclude non-cash, non-operational and non-recurring items, including stock-based compensation expense, employer payroll tax expense related to stock-based compensation, restructuring and other expenses and acquisition-related expenses.

    The principal limitation of non-GAAP research and development expenses, non-GAAP sales and marketing expenses and non-GAAP general and administrative expenses is that they exclude significant expenses that are required by GAAP to be recorded in our consolidated financial statements, including non-cash expenses, and the impact of non-recurring charges that we do not consider to be indicative of our ongoing core operations.

    Non-GAAP Net Income Attributable to Common Stockholders, Diluted and Non-GAAP Net Income Per Share Attributable to Common Stockholders, Diluted

    We define non-GAAP net income attributable to common stockholders, diluted and non-GAAP net income per share attributable to common stockholders, diluted (which we refer to as "non-GAAP diluted net income per share") as GAAP net income (loss) attributable to common stockholders and GAAP net income (loss) per share attributable to common stockholders, diluted, respectively, adjusted to exclude non-cash, non-operational and non-recurring items, including excess and obsolete inventory charges related to our AI-powered motion tracking technology transition, as applicable, stock-based compensation, amortization of acquired intangibles, employer payroll taxes related to stock-based compensation, restructuring and other expenses, acquisition-related expenses and the income tax effects related to non-GAAP adjustments.

    Free Cash Flow and Free Cash Flow Margin

    We define free cash flow as net cash provided by (used in) operating activities plus cash used for employer payroll taxes at IPO related to stock-based compensation less purchases of property, equipment and software (including capitalized internal-use software). We believe that free cash flow is a helpful indicator of liquidity that provides information to management and investors about the amount of cash generated or used by our operations that, after taking into account the employer payroll taxes paid as part of the vesting of shares at IPO as well as investments in property, equipment and software (including capitalized internal-use software), can be used for strategic initiatives, including investing in our business and strengthening our financial position. The principal limitation of free cash flow is that it does not represent the total increase or decrease in our cash balance for a given period. We define free cash flow margin as free cash flow divided by revenue.

    We adjust the following items from one or more of our non-GAAP financial measures:

    Excess and obsolete inventory charges. We exclude certain charges related to excess and obsolete inventory related to our AI-powered motion tracking technology transition, which was our strategic decision in the first half of 2023 to shift away from providing kits with tablets and wearable sensors. As part of this shift, we began to provide access to our platform through our app on members' personal smartphones or tablets and replaced sensors for members with our proprietary AI-powered motion tracking technology. We exclude these charges because we do not believe these expenses have a direct correlation to the operating performance of our business.

    Stock-based compensation expense. We exclude stock-based compensation expense, which is a non-cash expense, from certain of our non-GAAP financial measures because we believe that excluding this item provides meaningful supplemental information regarding our operating performance.

    Employer payroll tax expense related to stock-based compensation. We exclude expenses for employer payroll taxes related to stock-based compensation from certain of our non-GAAP financial measures because we believe that excluding this item provides meaningful supplemental information regarding operational performance. In particular, this expense is tied to the exercise, vesting or sale of underlying equity awards and the price of our common stock at the time of exercise, vesting or sale which may vary from period to period independent of the operating performance of our business.

    Amortization of intangible assets. We exclude amortization of intangible assets, which is a non-cash expense, from certain of our non-GAAP financial measures. Our expenses for amortization of intangible assets are inconsistent in amount and frequency because they are significantly affected by the timing, size of acquisitions and the inherent subjective nature of purchase price allocations. We exclude these amortization expenses because we do not believe these expenses have a direct correlation to the operating performance of our business.

    Restructuring and other expenses. We exclude certain charges that are mainly attributable to workforce reduction in order to simplify our operations and better align our resources with our priorities. We exclude these charges because we do not believe these charges have a direct correlation to the operating performance of our business.

    Acquisition-related expenses. We exclude certain charges that are attributable to acquiring businesses. We exclude these charges because we do not believe these charges have a direct correlation to the operating performance of our business.

    Income tax effect of non-GAAP adjustments. We exclude the valuation allowance that is attributable to our non-GAAP income beginning in 2025. For the quarter and year ended December 31, 2025 we determined the projected non-GAAP tax rate to be 20% and for the quarter and year ended December 31, 2024 we determined the projected non-GAAP tax rate to be (2)% and (14)%, respectively. These tax rates reflect current available information, as well as other factors and assumptions. We will periodically re-evaluate this tax rate, as necessary, for significant events, relevant tax law changes, material changes in the forecasted geographic earnings mix, and any significant transactions.

     

    HINGE HEALTH, INC.

    (unaudited)

    (in thousands, except percentages)

     

    Reconciliation of GAAP to Non-GAAP Financial Measures:

     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2025

     

    2024

     

    2025

     

    2024

    GAAP gross profit

     

    $

    144,027

     

     

    $

    96,088

     

     

    $

    468,222

     

     

    $

    299,902

     

    GAAP gross margin

     

     

    84

    %

     

     

    82

    %

     

     

    80

    %

     

     

    77

    %

    Non-GAAP adjustments:

     

     

     

     

     

     

     

     

    Excess and obsolete inventory charges (1)

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    1,812

     

    Stock-based compensation expense (2)

     

     

    1,126

     

     

     

    3

     

     

     

    18,969

     

     

     

    97

     

    Employer payroll tax expense related to stock-based compensation

     

     

    146

     

     

     

    —

     

     

     

    1,080

     

     

     

    —

     

    Amortization of intangible assets

     

     

    225

     

     

     

    94

     

     

     

    854

     

     

     

    378

     

    Restructuring and other expenses

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    691

     

    Non-GAAP gross profit

     

    $

    145,524

     

     

    $

    96,185

     

     

    $

    489,125

     

     

    $

    302,880

     

    Non-GAAP gross margin

     

     

    85

    %

     

     

    82

    %

     

     

    83

    %

     

     

    78

    %

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2025

     

    2024

     

    2025

     

    2024

    GAAP income (loss) from operations

     

    $

    27,256

     

     

    $

    20,910

     

     

    $

    (546,371

    )

     

    $

    (31,910

    )

    GAAP operating margin

     

     

    16

    %

     

     

    18

    %

     

     

    (93

    )%

     

     

    (8

    )%

    Non-GAAP adjustments:

     

     

     

     

     

     

     

     

    Excess and obsolete inventory charges (1)

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    1,812

     

    Stock-based compensation expense (2)

     

     

    17,172

     

     

     

    14

     

     

     

    643,009

     

     

     

    739

     

    Employer payroll tax expense related to stock-based compensation

     

     

    2,155

     

     

     

    —

     

     

     

    16,612

     

     

     

    (6,253

    )

    Amortization of intangible assets

     

     

    225

     

     

     

    94

     

     

     

    854

     

     

     

    378

     

    Restructuring and other expenses

     

     

    —

     

     

     

    (132

    )

     

     

    —

     

     

     

    8,495

     

    Acquisition-related expenses

     

     

    1,211

     

     

     

    543

     

     

     

    5,351

     

     

     

    643

     

    Non-GAAP income (loss) from operations

     

    $

    48,019

     

     

    $

    21,429

     

     

    $

    119,455

     

     

    $

    (26,096

    )

    Non-GAAP operating margin

     

     

    28

    %

     

     

    18

    %

     

     

    20

    %

     

     

    (7

    )%

    (1)

    Reflects our strategic decision in the first half of 2023 to shift away from providing kits with tablets and wearable sensors. As part of this shift, we began to provide access to our platform through our app on members' personal smartphones or tablets and replaced all sensors for members with our proprietary AI-powered motion tracking technology.

    (2)

    Stock-based compensation expense:

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2025

     

    2024

     

    2025

     

    2024

    Cost of revenue

     

    $

    1,126

     

     

    $

    3

     

     

    $

    18,969

     

     

    $

    97

     

    Research and development

     

     

    7,519

     

     

     

    5

     

     

     

    264,587

     

     

     

    202

     

    Sales and marketing

     

     

    5,034

     

     

     

    5

     

     

     

    106,043

     

     

     

    223

     

    General and administrative

     

     

    3,493

     

     

     

    1

     

     

     

    253,410

     

     

     

    217

     

     

     

    $

    17,172

     

     

    $

    14

     

     

    $

    643,009

     

     

    $

    739

     

     

    HINGE HEALTH, INC.

    (unaudited)

    (in thousands, except per share amounts)

     

     

     

     

     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2025

     

    2024

     

    2025

     

    2024

    GAAP net income (loss) attributable to common stockholders, diluted

     

    $

    31,144

     

     

    $

    6,676

     

     

    $

    (424,087

    )

     

    $

    (11,933

    )

    Non-GAAP adjustments:

     

     

     

     

     

     

     

     

    Excess and obsolete inventory charges (1)

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    1,812

     

    Stock-based compensation expense (2)

     

     

    17,172

     

     

     

    14

     

     

     

    643,009

     

     

     

    739

     

    Employer payroll tax expense related to stock-based compensation

     

     

    2,155

     

     

     

    —

     

     

     

    16,612

     

     

     

    (6,253

    )

    Amortization of intangible assets

     

     

    225

     

     

     

    94

     

     

     

    854

     

     

     

    378

     

    Restructuring and other expenses

     

     

    —

     

     

     

    (132

    )

     

     

    —

     

     

     

    8,495

     

    Acquisition-related expenses

     

     

    1,211

     

     

     

    543

     

     

     

    5,351

     

     

     

    643

     

    Income tax effect of non-GAAP adjustments

     

     

    (10,475

    )

     

     

    (417

    )

     

     

    (26,715

    )

     

     

    (85

    )

    Other dilutive

     

     

    (305

    )

     

     

    (78

    )

     

     

    (53,676

    )

     

     

    —

     

    Non-GAAP net income (loss) attributable to common stockholders, diluted

     

    $

    41,127

     

     

    $

    6,700

     

     

    $

    161,348

     

     

    $

    (6,204

    )

     

     

     

     

     

     

     

     

     

    Non-GAAP net income (loss) attributable to common stockholders per share, diluted

     

    $

    0.49

     

     

    $

    0.40

     

     

    $

    2.62

     

     

    $

    (0.46

    )

     

     

     

     

     

     

     

     

     

    Weighted average shares used in computing non-GAAP net income (loss) per share attributable to common stockholders, diluted

     

     

    84,533

     

     

     

    16,576

     

     

     

    61,471

     

     

     

    13,558

     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2025

     

    2024

     

    2025

     

    2024

    GAAP net income (loss) per share attributable to common stockholders, diluted

     

    $

    0.37

     

     

    $

    0.40

     

     

    $

    (7.77

    )

     

    $

    (0.88

    )

    Non-GAAP adjustments:

     

     

     

     

     

     

     

     

    Excess and obsolete inventory charges (1)

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    0.13

     

    Stock-based compensation expense (2)

     

     

    0.20

     

     

     

    —

     

     

     

    10.46

     

     

     

    0.05

     

    Employer payroll tax expense related to stock-based compensation

     

     

    0.03

     

     

     

    —

     

     

     

    0.27

     

     

     

    (0.46

    )

    Amortization of intangible assets

     

     

    —

     

     

     

    0.01

     

     

     

    0.01

     

     

     

    0.03

     

    Restructuring and other expenses

     

     

    —

     

     

     

    (0.01

    )

     

     

    —

     

     

     

    0.63

     

    Acquisition-related expenses

     

     

    0.01

     

     

     

    0.03

     

     

     

    0.09

     

     

     

    0.05

     

    Income tax effect on non-GAAP adjustments

     

     

    (0.12

    )

     

     

    (0.03

    )

     

     

    (0.44

    )

     

     

    (0.01

    )

    Non-GAAP net income (loss) per share attributable to common stockholders, diluted (3)

     

    $

    0.49

     

     

    $

    0.40

     

     

    $

    2.62

     

     

    $

    (0.46

    )

    (1)

    For details on excess and obsolete inventory charges, see above.

    (2)

    For details on stock-based compensation expense, see above.

    (3)

    Some columns may not add due to rounding.

     

    HINGE HEALTH, INC.

    (unaudited)

    (in thousands, except for percentages)

     

     

     

     

     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2025

     

    2024

     

    2025

     

    2024

    GAAP research and development

     

    $

    32,755

     

     

    $

    22,371

     

     

    $

    368,137

     

     

    $

    100,839

     

    GAAP research and development as a percentage of revenue

     

     

    19

    %

     

     

    19

    %

     

     

    63

    %

     

     

    26

    %

    Non-GAAP adjustments:

     

     

     

     

     

     

     

     

    Stock-based compensation expense (1)

     

     

    (7,519

    )

     

     

    (5

    )

     

     

    (264,587

    )

     

     

    (202

    )

    Employer payroll tax expense related to stock-based compensation

     

     

    (1,478

    )

     

     

    —

     

     

     

    (8,643

    )

     

     

    2,852

     

    Restructuring and other expenses

     

     

    —

     

     

     

    139

     

     

     

    —

     

     

     

    (4,144

    )

    Acquisition-related expenses

     

     

    (1,223

    )

     

     

    —

     

     

     

    (5,198

    )

     

     

    —

     

    Non-GAAP research and development

     

    $

    22,535

     

     

    $

    22,505

     

     

    $

    89,709

     

     

    $

    99,345

     

    Non-GAAP research and development as a percentage of revenue

     

     

    13

    %

     

     

    19

    %

     

     

    15

    %

     

     

    25

    %

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2025

     

    2024

     

    2025

     

    2024

    GAAP sales and marketing

     

    $

    59,487

     

     

    $

    35,451

     

     

    $

    316,951

     

     

    $

    167,058

     

    GAAP sales and marketing as a percentage of revenue

     

     

    35

    %

     

     

    30

    %

     

     

    54

    %

     

     

    43

    %

    Non-GAAP adjustments:

     

     

     

     

     

     

     

     

    Stock-based compensation expense (1)

     

     

    (5,034

    )

     

     

    (5

    )

     

     

    (106,043

    )

     

     

    (223

    )

    Employer payroll tax expense related to stock-based compensation

     

     

    (361

    )

     

     

    —

     

     

     

    (3,018

    )

     

     

    —

     

    Restructuring and other expenses

     

     

    —

     

     

     

    (4

    )

     

     

    —

     

     

     

    (2,118

    )

    Non-GAAP sales and marketing

     

    $

    54,092

     

     

    $

    35,442

     

     

    $

    207,890

     

     

    $

    164,717

     

    Non-GAAP sales and marketing as a percentage of revenue

     

     

    32

    %

     

     

    30

    %

     

     

    35

    %

     

     

    42

    %

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2025

     

    2024

     

    2025

     

    2024

    GAAP general and administrative

     

    $

    24,529

     

     

    $

    17,356

     

     

    $

    329,505

     

     

    $

    63,915

     

    GAAP general and administrative as a percentage of revenue

     

     

    14

    %

     

     

    15

    %

     

     

    56

    %

     

     

    16

    %

    Non-GAAP adjustments:

     

     

     

     

     

     

     

     

    Stock-based compensation expense (1)

     

     

    (3,493

    )

     

     

    (1

    )

     

     

    (253,410

    )

     

     

    (217

    )

    Employer payroll tax expense related to stock-based compensation

     

     

    (170

    )

     

     

    —

     

     

     

    (3,871

    )

     

     

    3,401

     

    Restructuring and other expenses

     

     

    —

     

     

     

    (4

    )

     

     

    —

     

     

     

    (1,543

    )

    Acquisition-related expenses

     

     

    12

     

     

     

    (543

    )

     

     

    (153

    )

     

     

    (643

    )

    Non-GAAP general and administrative

     

    $

    20,878

     

     

    $

    16,808

     

     

    $

    72,071

     

     

    $

    64,913

     

    Non-GAAP general and administrative as a percentage of revenue

     

     

    12

    %

     

     

    14

    %

     

     

    12

    %

     

     

    17

    %

    (1)

    For details on stock-based compensation expense, see above.

     

    HINGE HEALTH, INC.

    (unaudited)

    (in thousands, except for percentages)

     

     

     

     

     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2025

     

    2024

     

    2025

     

    2024

    Net cash provided by operating activities

     

    $

    63,895

     

     

    $

    38,339

     

     

    $

    171,441

     

     

    $

    49,002

     

    Operating cash flow margin

     

     

    37

    %

     

     

    33

    %

     

     

    29

    %

     

     

    13

    %

    Adjustment for employer taxes at IPO related to stock-based compensation

     

     

    —

     

     

     

    —

     

     

     

    14,227

     

     

     

    —

     

    Less purchases of property, equipment and software (including capitalized internal use software)

     

     

    (2,363

    )

     

     

    (1,030

    )

     

     

    (6,064

    )

     

     

    (3,773

    )

    Free cash flow

     

    $

    61,532

     

     

    $

    37,309

     

     

    $

    179,604

     

     

    $

    45,229

     

    Free cash flow margin

     

     

    36

    %

     

     

    32

    %

     

     

    31

    %

     

     

    12

    %

    Net cash (used in) provided by investing activities

     

    $

    (37,696

    )

     

    $

    (3,114

    )

     

    $

    (113,763

    )

     

    $

    18,312

     

    Net cash used in financing activities

     

    $

    (79,545

    )

     

    $

    (2,335

    )

     

    $

    (150,468

    )

     

    $

    (2,202

    )

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260209499354/en/

    Investor Relations Contact:

    [email protected]



    Media Contact:

    [email protected]

    Get the next $HNGE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HNGE

    DatePrice TargetRatingAnalyst
    1/9/2026$68.00Overweight
    Wells Fargo
    9/5/2025$56.00Neutral
    Robert W. Baird
    7/14/2025$58.00Mkt Outperform
    Citizens JMP
    6/16/2025Outperform
    William Blair
    6/16/2025$48.00Buy
    Truist
    6/16/2025$48.00Buy
    Stifel
    6/16/2025$45.00Outperform
    Raymond James
    6/16/2025$41.00Overweight
    Piper Sandler
    More analyst ratings

    $HNGE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Hinge Health Inc.

    SCHEDULE 13G/A - Hinge Health, Inc. (0001673743) (Subject)

    2/17/26 4:54:23 PM ET
    $HNGE
    EDP Services
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Hinge Health Inc.

    SCHEDULE 13G/A - Hinge Health, Inc. (0001673743) (Subject)

    2/13/26 6:10:12 PM ET
    $HNGE
    EDP Services
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Hinge Health Inc.

    SCHEDULE 13G/A - Hinge Health, Inc. (0001673743) (Subject)

    2/13/26 5:25:02 PM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Robinson Elliott sold 0 shares (SEC Form 4)

    4 - Hinge Health, Inc. (0001673743) (Issuer)

    2/19/26 7:12:52 PM ET
    $HNGE
    EDP Services
    Technology

    CEO & Co-Founder Perez Daniel Antonio converted options into 7,260 shares and gifted 7,260 shares (SEC Form 4)

    4 - Hinge Health, Inc. (0001673743) (Issuer)

    2/18/26 6:42:23 PM ET
    $HNGE
    EDP Services
    Technology

    Director Robinson Elliott sold 0 shares (SEC Form 4)

    4 - Hinge Health, Inc. (0001673743) (Issuer)

    2/17/26 4:15:05 PM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hinge Health reports fourth quarter and full year 2025 financial results

    Hinge Health, Inc. (NYSE:HNGE) today announced record financial results for the quarter and year ended December 31, 2025. "We closed out the year with an exceptional quarter and a strong selling season, driving our highest win rates to date and greatest number of eligible lives added in any year," said Daniel Perez, Co-Founder and CEO, Hinge Health. "Our commercial momentum, combined with expanding margins and strong cash generation, gives us confidence in our ability to continue automating care delivery, sustain our position as a leader in digital musculoskeletal care, and drive attractive growth and increased margins in 2026." Fourth Quarter 2025 Financial Highlights: Revenue incre

    2/10/26 4:05:00 PM ET
    $HNGE
    EDP Services
    Technology

    Hinge Health's 2026 State of Musculoskeletal Care Report reveals stark gaps in traditional care

    Today, Hinge Health (NYSE:HNGE) released its sixth annual State of Musculoskeletal (MSK) Care Report, revealing how today's fragmented healthcare system leaves many people unsure how to pursue treatment for MSK pain. Hinge Health surveyed 1,000 people living with MSK pain alongside 295 healthcare providers to understand the systemic challenges and opportunities for industry-wide improvements. The dual-perspective survey – along with real patient and provider stories – maps a clear path to more effective, unified care. "While Hinge Health's digital physical therapy program has dramatically increased access, MSK care still feels like a maze for too many people," said Dr. Jeffrey Krauss, MD,

    1/15/26 11:00:00 AM ET
    $HNGE
    EDP Services
    Technology

    Hinge Health to announce fourth quarter and full year 2025 financial results on February 10, 2026

    Hinge Health, Inc. (NYSE:HNGE) announced today that it will report its financial results for the fourth quarter and full year 2025 after the U.S. financial markets close on Tuesday, February 10, 2026. Hinge Health will also host an earnings conference call to discuss its results and guidance at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. The live audio webcast of the earnings conference call will be available on the Hinge Health Investor Relations website at ir.hingehealth.com. A replay of the webcast will be available on the same website shortly after its completion. About Hinge Health Hinge Health is focused on scaling and automating the delivery of health care, st

    1/14/26 9:00:00 AM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Hinge Health with a new price target

    Wells Fargo initiated coverage of Hinge Health with a rating of Overweight and set a new price target of $68.00

    1/9/26 9:05:22 AM ET
    $HNGE
    EDP Services
    Technology

    Robert W. Baird initiated coverage on Hinge Health with a new price target

    Robert W. Baird initiated coverage of Hinge Health with a rating of Neutral and set a new price target of $56.00

    9/5/25 7:59:54 AM ET
    $HNGE
    EDP Services
    Technology

    Citizens JMP initiated coverage on Hinge Health with a new price target

    Citizens JMP initiated coverage of Hinge Health with a rating of Mkt Outperform and set a new price target of $58.00

    7/14/25 8:51:47 AM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    Financials

    Live finance-specific insights

    View All

    Hinge Health to announce fourth quarter and full year 2025 financial results on February 10, 2026

    Hinge Health, Inc. (NYSE:HNGE) announced today that it will report its financial results for the fourth quarter and full year 2025 after the U.S. financial markets close on Tuesday, February 10, 2026. Hinge Health will also host an earnings conference call to discuss its results and guidance at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. The live audio webcast of the earnings conference call will be available on the Hinge Health Investor Relations website at ir.hingehealth.com. A replay of the webcast will be available on the same website shortly after its completion. About Hinge Health Hinge Health is focused on scaling and automating the delivery of health care, st

    1/14/26 9:00:00 AM ET
    $HNGE
    EDP Services
    Technology

    Hinge Health to announce third quarter 2025 financial results on November 4, 2025

    Hinge Health, Inc. (NYSE:HNGE) announced today that it will report its financial results for the quarter ended September 30, 2025, after the U.S. markets close on Tuesday, November 4, 2025. Hinge Health will also host an earnings conference call to discuss its results and guidance at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. The live audio webcast of the earnings conference call will be available on the Hinge Health Investor Relations website at ir.hingehealth.com. A replay of the webcast will be available on the same website shortly after its completion. About Hinge Health Hinge Health is focused on scaling and automating the delivery of health care, starting with

    10/1/25 5:00:00 PM ET
    $HNGE
    EDP Services
    Technology

    Hinge Health Reports Second Quarter 2025 Financial Results

    Hinge Health, Inc. (NYSE:HNGE) today announced financial results for the second quarter ended June 30, 2025. "In Q2 we delivered year-over-year revenue growth of 55% and a strong free cash flow margin, underlining the market's embrace of our AI-powered platform," said Daniel Perez, Co-Founder and CEO, Hinge Health. "The journey of automating healthcare delivery will be challenging, but we're excited about our momentum and are moving with haste to capture this opportunity." Second Quarter 2025 Financial Highlights: Revenue increased 55% year-over-year to $139.1 million compared to revenue of $89.8 million in Q2 2024. GAAP gross margin was 70% compared to 74% in Q2 2024. Non-GAAP gr

    8/5/25 4:05:00 PM ET
    $HNGE
    EDP Services
    Technology